BioCentury

8:00 AM GMT, Mar 27, 2006
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Removing toxicity

Liver toxicity or unmanageable pharmacokinetics have killed a lot of drugs over the years. But with this week's announcement of Phase I safety data for a nucleotide reverse transcriptase inhibitor that had been shelved due to toxicity, Heidelberg Pharma AG believes it now has sound evidence to prove that its Enhanced Pro-Drug Technology (EPD) platform can salvage

Read the full 576 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.